Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.
Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS.
J Clin Endocrinol Metab. 2013 Sep;98(9):3671-7. doi: 10.1210/jc.2013-1954. Epub 2013 Jul 3.
Propylthiouracil-induced hepatic damage.
Weiss M, Hassin D, Bank H.
Arch Intern Med. 1980 Sep;140(9):1184-5.
Hepatic incidentaloma: An asymptomatic ectopic thyroid tissue.
Di Stefano C, Guarnotta V, Barbaccia M, Paratore R, La Monica R, Lo Casto A, Midiri M, Gruttadauria S, Giordano C, Richiusa P.
Front Endocrinol (Lausanne). 2022 Dec 12;13:1066188. doi: 10.3389/fendo.2022.1066188. eCollection 2022.
Environmental pollutants and the thyroid.
Pearce EN, Braverman LE.
Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):801-13. doi: 10.1016/j.beem.2009.06.003.
[Localizations and consequences].
Dupond JL, Gil H.
Rev Prat. 1997 Oct 15;47(16):1767-72.
The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland.
Curran PG, DeGroot LJ.
Endocr Rev. 1991 May;12(2):135-50. doi: 10.1210/edrv-12-2-135.
Hepatic injury caused by benzbromarone.
van der Klauw MM, Houtman PM, Stricker BH, Spoelstra P.
J Hepatol. 1994 Mar;20(3):376-9. doi: 10.1016/s0168-8278(94)80011-1.
Hepatic dysfunction related to thyrotropin receptor antibody in patients with Graves' disease.
He K, Hu Y, Xu XH, Mao XM.
Exp Clin Endocrinol Diabetes. 2014 Jun;122(6):368-72. doi: 10.1055/s-0034-1375667. Epub 2014 Jun 18.
Factors affecting drug-induced liver injury: antithyroid drugs as instances.
Heidari R, Niknahad H, Jamshidzadeh A, Abdoli N.
Clin Mol Hepatol. 2014 Sep;20(3):237-48. doi: 10.3350/cmh.2014.20.3.237. Epub 2014 Sep 25.
Management of metabolic and miscellaneous disorders.
Kasprisin DO, Strauss RG, Ciavarella D, Gilcher RO, Kiprov DD, Klein HG, McLeod BC.
J Clin Apher. 1993;8(4):231-41. doi: 10.1002/jca.2920080405.
